Mergers & Acquisitions - Biotechnology, Licensing


Current filters:


Popular Filters

1 to 25 of 27 results

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum


Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Second collaboration between FORMA Therapeutics and Celgene


Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Abide Therapeutics in deal with Celgene on immune disorders research


Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company


Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products


French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Advaxis rockets on out-licensing ADXS-HPV in Asia


Shares of US cancer drug developer Advaxis leapt 22% to $4.38 in pre-market trading as the company revealed…

AdvaxisADXS-HPVBiotechnologyGlobal BioPharmaLicensingMergers & AcquisitionsOncologyTaiwan Biotech

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene


US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring


US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Collaboration agreement between French firms Vect-Horus and AAA


French biotech company Vect-Horus has signed a scientific collaboration agreement with Advanced Accelerator…

Advanced Accelerator ApplicationsBiotechnologyCNS DiseasesEuropeLicensingMergers & AcquisitionsVect-Horus

Rainbow Coral narrows list of regenerative medicine targets


USA-based Rainbow Coral Corp says it has opened talks with its top target in the regenerative medicine…

BiotechnologyLicensingMergers & AcquisitionsRainbow Biosciences

Acetylon snags $100 million upfront cash and acquisition option


Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Italy's Chiesi gains rights to uniQure's Glybera


Netherlands-based venture capital backed human gene therapy firm uniQure has signed collaboration agreements…

BiotechnologyChiesi FarmaceuticiGlyberaLicensingMergers & AcquisitionsPharmaceuticaluniQure

MorphoSys and Celgene in deal to advance MOR202 for multiple myeloma


German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world's largest independent…

BiotechnologyCelgeneEuropeLicensingMergers & AcquisitionsMOR202MorphoSysOncology

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill


A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

Two life sciences IPOs and strengthening markets offer encouragement to Biotech sector


Two companies focused on infectious disease successfully completed initial public offerings (IPOs) in…

BiotechnologyFinancialLicensingMergers & Acquisitions

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca


German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS),…

AstraZenecaBiotechnologyCell Culture Service GmbHDiabetesEvotecLicensingMedImmuneMergers & AcquisitionsPharmaceutical

Amgen and KPCB to create Atara Biotherapeutics; Banner Pharmacaps changes hands


The world's largest biotech firm Amgen (Nasdaq: AMGN) and venture capital group Kleiner Perkins Caufield…

AmgenAtara BiotherapeuticsBanner PharmacapsBiotechnologyLicensingMergers & AcquisitionsNephrology and HepatologyOncologyPatheonPharmaceuticalProduction

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal


Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Pharming considers options, including a sale of the company


Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is…

BiotechnologyLicensingMergers & AcquisitionsPharmingRare diseasesResearchRuconest

Forest acquires rights to Nabriva antibacterial and option to buy firm


US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech…

Antibiotics and Infectious diseasesBC-3781BiotechnologyForest LaboratoriesLicensingMergers & AcquisitionsNabriva TherapeuticsPharmaceutical

1 to 25 of 27 results

Back to top